ECM
CTKB icon

Everence Capital Management’s Cytek Biosciences CTKB Stock Holding History

Everence Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,760
Closed -$93K – 866
2024
Q3 		$93K Buy
16,760
+2,900
+21% +$16.4K 0.01% 745
2024
Q2 		$83 Hold
13,860
– – 0.01% 737
2024
Q1 		$93 Hold
13,860
– – 0.01% 754
2023
Q4 		$126K Sell
13,860
-2,160
-13% -$13.6K 0.01% 738
2023
Q3 		$88 Buy
+16,020
New +$129K 0.01% 738

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Everence Capital Management's CTKB Position: Q4 2024 in Review

Everence Capital Management sold out of Cytek Biosciences (CTKB) in Q4 2024, closing a stake of 16,760 shares — an estimated $93K sold.

Everence Capital Management first reported a position in CTKB in Q3 2023 and held it in 5 quarters. The position peaked at $126K in Q4 2023. 152 funds tracked by Wall St. Rank hold CTKB as of Q4 2024.

  • Everence Capital Management reported no remaining Cytek Biosciences position as of Q4 2024 after selling out during the quarter.
  • Everence Capital Management sold 16,760 Cytek Biosciences shares in Q4 2024, an estimated $93K.
  • Everence Capital Management first reported a position in Cytek Biosciences in Q3 2023 and held it in 5 quarters.
  • Everence Capital Management's Cytek Biosciences position peaked at $126K in Q4 2023.
  • 152 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2024.

Based on Everence Capital Management's 13F filing for Q4 2024, filed 3 Jan 2025.